[Special Stock] Pharmicell's Stock Soars Following US Monkeypox Emergency Declaration

[Asia Economy Reporter Minji Lee] Pamicell, a stock related to monkeypox, is showing a sharp rise during trading hours.

At 10:54 AM on the 5th, Pamicell was trading at 13,900 KRW, up 10.32% compared to the previous trading day.

The U.S. government's declaration of a public health emergency related to monkeypox is analyzed to have influenced the stock price. This measure aims to strengthen the federal government's response to monkeypox, which continues to see increasing infections worldwide. Currently, the number of monkeypox cases in the U.S. has surpassed 6,600 since the first case was reported in mid-May, indicating a spreading trend.

The World Health Organization (WHO) had already declared monkeypox an international public health emergency on the 23rd of last month.

Since 2007, Pamicell has been the exclusive supplier of HDP-Tosylate, a key intermediate used in the smallpox treatment drug 'Brincidofovir' being developed by the U.S. biotech company Chimerix.